# Neuracle

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuracle

- Industry: Healthcare Specialists
- Headquarters: Changzhou, China
- Website: www.neuracle.cn
- Total disclosed funding: $24M
- Latest round: Series C (Dec 15, 2022)
- Investors on record: 6

## About

Established in 2011 and based in Changzhou, China, Neuracle is a solution provider with a core team from Top 5 Global Brain-Computer Intelligence Research Laboratories and medical market experts in the field of clinical neurology. In 2012, it completed the construction of Jiangsu Changzhou research, development and production base. The company won the special support of the National Twelfth Five-Year Plan and obtained a medical device production license in 2013. In 2015, the institution raised CNY 12 million in angel funding from Co-Win Ventures and Roton Capital. In 2017, it obtained the registration certificate of digital electroencephalography machine medical equipment and officially entered the medical field. The company raised CNY 30 million in pre-A funding from Roton Capital in 2018. In 2019, it raised CNY 60 million in series A funding from Baidu Ventures, Co-Win Ventures and Tsinghua Holdings Capital. In 2021, the company raised over CNY 100 million in series B funding from Sequoia Capital, Co-Win Ventures and Roton Capital. In November 2024, the firm closed a series D funding.

Neuracle is a high-tech enterprise with independent innovation of "brain-computer interface" technology as the core, specializing in the research and development, production, sales and technical services of related equipment of brain-computer interface system. The company relies on the international leading brain-computer interface technology which is independently developed by Tsinghua University, committed to providing professional and complete solutions for neuroscience innovation research and clinical neurological disease diagnosis, treatment and rehabilitation research. For example: The digital EEG machine is a product independently developed by Neuracle. It is manufactured with scientific research level technology and has excellent anti-interference ability. It can collect high-quality signals in complex ICU environments. It has waveform measurement tool which can measure waveform amplitude and frequency. The digital EEG machine can be selected 8/16/32/40 to meet the needs of different departments. A variety of montage editors for clinical use. The products of neuracle were widely used in scientific research fields such as neuroscience, psychology, human factors engineering, Kinematics, management, etc. Besides, they are also used in clinical medical fields such as clinical neurological disease diagnosis, treatment and rehabilitation engineering.

The company’s revenue is generated by providing clinical neurological disease diagnosis, treatment and rehabilitation solutions.

The company will use the series D funding for product development and market expansion.

## Funding rounds

- Series C, Dec 15, 2022 — Green Pine Capital Partners
- Series B, Mar 19, 2021, $15M — Hong Shan, Co-Win Ventures, Roton Capital
- Series A, Aug 26, 2019, $8.5M — T-Capital, Co-Win Ventures, Baidu Ventures

## Investors

- T-Capital — Series A
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A, Series B
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- Hong Shan — Series B
- Roton Capital (https://capitalatlas.ai/funds/roton-capital) — Series B
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series C